Tag:

drug prices

Latest Headlines

Latest Headlines

Cancer drug spending to leap at least 34%

Cancer care advances. So does the cost of treatment. U.S. spending on oncology drugs could grow by 10 percent per year through 2013, Medco Health Solutions has found, partly because patients are

GSK cuts prices on 'essential' Kenyan meds by 50%

Following through on a pledge to reduce the cost of its meds in the developing world, GlaxoSmithKline is rolling out price cuts in Kenya. The company's Kenyan unit will reduce prices on "essential"

Can drugmakers keep up the 'crazy' price increases?

Hiking drug prices to boost sales is a strategy that's been working--but it can't last. That's what pharma industry executives have been saying this week at the Reuters Health Summit. As Bain &

Gilead's U.S. pricing on HIV meds draws fire

Gilead Sciences chief John Martin (photo) figures his HIV drugs won't earn much in under-developed countries. And if the drugs won't earn much there, then the patents on them aren't worth much,

AZ chief: Industry stats skewed by overstated U.S. prices

Pharma sales stats could be all wrong--at least that's what AstraZeneca CEO David Brennan (photo) told the Reuters Health Summit. List prices are just that, and real prices are somewhat lower. On

ISP passes on ingredient price hikes to drugmakers

Better alert purchasing because drug ingredient prices are going up, up, up again. All of its biocide products--especially those containing 3-Iodo-Propynyl-Butylcarbamate--are subject to a 10 percent

Par to pay $153M in pricing lawsuit settlement

Par Pharmaceutical has agreed to pay $153 million to settle drug pricing lawsuits alleging the company caused government entities to pay inflated reimbursements. Report

UK docs can now strike risk-sharing deals with pharma

Changes in the UK pharma code of ethics will allow doctors' groups to negotiate risk-sharing price deals with drugmakers, Pulse Today reports, clearing the way for GPs to use outcomes to determine

NICE issues final rebuff to Novartis' Afinitor

Novartis' battle to win over the UK's cost-effectiveness watchdog to its kidney cancer treatment Afinitor has hit a dead end, as the National Institute for Health and Clinical Excellence determined

Big pharma objects to India's pricing request

India is clamping down on price hikes by global drugmakers. It has nixed increases on imports when manufacturers won't share pricing details. Eli Lilly and Novo Nordisk are among the multinationals